Merck KGaA (MKKGY)
OTCMKTS
· Delayed Price · Currency is USD
26.33
+0.18 (0.69%)
Jun 27, 2025, 3:58 PM EDT
Merck KGaA Employees
Merck KGaA had 59,020 employees as of December 31, 2024. The number of employees decreased by 3,888 or -6.18% compared to the previous year.
Employees
59,020
Change (1Y)
-3,888
Growth (1Y)
-6.18%
Revenue / Employee
$368,017
Profits / Employee
$48,652
Market Cap
54.94B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 59,020 | -3,888 | -6.18% |
| Dec 31, 2023 | 62,908 | -1,324 | -2.06% |
| Dec 31, 2022 | 64,232 | 3,898 | 6.46% |
| Dec 31, 2021 | 60,334 | 2,207 | 3.80% |
| Dec 31, 2020 | 58,127 | 1,056 | 1.85% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Endo, Inc. | 3,116 |
| Elite Pharmaceuticals | 64 |
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| American Oncology Network | 1,914 |
| CytoDyn | 9 |
| Northwest Biotherapeutics | 25 |
| Silence Therapeutics | 116 |
Merck KGaA News
- 9 days ago - Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit in Dubai - Business Upturn
- 9 days ago - MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant - Financial Post
- 18 days ago - China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor - Benzinga
- 18 days ago - China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor - Business Wire
- 18 days ago - China's Center for Drug Evaluation Accepts Merck's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor - Business Wire
- 4 weeks ago - Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor - Benzinga
- 4 weeks ago - Merck Foundation Chairman and CEO Meet Nigeria First Lady to Underscore Their Long-Term Commitment to Transform Patient Care Landscape in the Country - Business Upturn
- 5 weeks ago - EMD Serono Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash - Benzinga